tirzepatide make you hungry Why am I still on tirzepatide? Common causes explained Why am I still hungry

And for understanding the legal framework that governs peptide access in the United States, our peptide legality guide breaks down federal and state regulations

ClinicalTrials.gov TRIUMPH-1: A Master Protocol to Investigate the Efficacy and Safety of Retatrutide (LY3437943) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (NCT05929066)

Whether the findings translate to non-obese models, or to cancer types not driven by metabolic dysregulation, remains an open research question

NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage